Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke
Algernon Pharmaceuticals CEO Christopher Moreau joined …
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After …
Expert Investor Rates Algernon Pharmaceuticals as an Immediate Buy
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock …
Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough
Proactive Investors Interview – Algernon Pharmaceuticals …
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co. …
MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs
Since covering Algernon 6 months ago, the biotech sector has …
Research Capital Corporation – Additional Phase 2a Analysis by a Chronic Cough KOL
We are maintaining our SPECULATIVE BUY rating & C$25 Target …
Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
Most idiopathic pulmonary fibrosis (IPF) patients treated …
Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity …
Research Capital Corporation – Breathing Easier – Liftoff! – IPF Phase 2a Data Hits
Research Capital Corporation – Breathing Easier – …
Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF …
Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?
Can the Psychedelic Drug DMT Take Algernon to the Next Level? Can a …
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease …
Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022
Proactive Investors Interview – Algernon Pharmaceuticals Phase …
Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon …
Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Listen to Cyndi Edwards, host of Streetwise Live!, speak with …
Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve …
Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve …
This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Biotech is hard. It is full of failure and the frustrations of …
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve …
Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes …
Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
The pharmaceutical industry is famous for its high …
Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study
Algernon Pharmaceuticals CEO Christopher J. …
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4
The interview series with Algernon Pharmaceuticals CEO …
Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud
Algernon Pharmaceuticals CEO Christopher J. Moreau …
Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
Algernon Presents Psychiatrist and Author Rick Strassman, MD on a …
Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT
Algernon Pharmaceuticals CEO Christopher J. Moreau …
Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO
Market Herald Powerplay host Dave Jackson interviews …
DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows
The psychedelic drug N,N-Dimethyltryptamine (DMT) has been …
Proactive Investors Interview – Algernon Pharmaceuticals files a pre-IND meeting request with US FDA for Ifenprodil Small Cell Lung Cancer Study
Proactive Investors Interview – Algernon Pharmaceuticals files …
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3
The interview series with Algernon Pharmaceuticals CEO …
The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons
A preclinical study by pharmaceutical development …
Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2
The interview series with Algernon Pharmaceuticals CEO …
Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Proactive Investors Interview – Algernon Pharmaceutical’s …
Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Psychedelic Finance – Interview with Christopher J. Moreau | …
Interview with Dr. William North – Algernon Pharmaceuticals Lead Consultant for its Small Cell Lung Cancer Ifenprodil Research Program
Interview with Dr. William North – Algernon …